Estudio REALIST (REsiduAl risk, LIpids and Standard Therapies): Un análisis del Riesgo Residual dependiente del perfil lipídico en el síndrome coronario agudo-Reference-Cited by-同舟云学术

Estudio REALIST (REsiduAl risk, LIpids and Standard Therapies): Un análisis del Riesgo Residual dependiente del perfil lipídico en el síndrome coronario agudo

Published:2011-01 Issue:1 Volume:58 Page:38-47
ISSN:1575-0922
Container-title:Endocrinología y Nutrición
language:es
Short-container-title:Endocrinología y Nutrición

Author:

Millán Núñez-Cortés Jesús,Montoya Juan Pedro-Botet,Salas Xavier Pintó,Mijares Antonio Hernández,Carey Vincent J.,Hermans Michel P.,Sacks Frank M.,Fruchart Jean-Charles

Publisher

Elsevier BV

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism

Reference54 articles.

1. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Final report. Circulation. 2002;106:3143–421.

2. European guidelines on cardiovascular disease prevention in clinical practice. Executive summary;EHJ.,2007

3. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update;Smith;Circulation.,2006

4. Primary prevention of cardiovascular diseases in people with diabetes mellitus. A Scientific Statement from the American Heart Association and the American Diabetes Association;Buse;Circulation,2007

5. Standards of medical care in diabetes-2008;Diabetes Care.,2008

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Selective peroxisome proliferator-activated receptorα modulators (SPPARMα): The next generation of peroxisome proliferator-activated receptor α-agonists;Cardiovascular Diabetology;2013

2. Alteraciones del metabolismo de las lipoproteínas;Medicine - Programa de Formación Médica Continuada Acreditado;2012-10

3. HIPERHOMOCISTEINEMIA EN PACIENTES CON DIABETES MELLITUS TIPO 2 DE UNA UNIDAD DE MEDICINA FAMILIAR DE HERMOSILLO, SONORA;BIOtecnia;2011-08-30

4. Reducing vascular events risk in patients with dyslipidaemia: an update for clinicians;Therapeutic Advances in Chronic Disease;2011-08-04

5. Primary prevention of coronary heart disease: integration of new data, evolving views, revised goals, and role of rosuvastatin in management. A comprehensive survey;Drug Design, Development and Therapy;2011-06